Labcorp Holdings Inc. (ETR:N6B)
Germany · Delayed Price · Currency is EUR | Market Cap | 26.45B +34.4% |
| Revenue (ttm) | 12.85B +6.0% |
| Net Income | 884.12M +17.4% |
| EPS | 10.91 +19.6% |
| Shares Out | n/a |
| PE Ratio | 29.69 |
| Forward PE | 19.00 |
| Dividend | 2.49 (0.77%) |
| Ex-Dividend Date | Nov 24, 2026 |
| Volume | n/a |
| Open | 326.00 |
| Previous Close | 328.00 |
| Day's Range | 324.00 - 326.00 |
| 52-Week Range | 224.00 - 328.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
About Labcorp Holdings
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseas... [Read more]
Financial Performance
In 2025, Labcorp Holdings's revenue was $13.95 billion, an increase of 7.25% compared to the previous year's $13.01 billion. Earnings were $876.50 million, an increase of 17.49%.
Financial numbers in USD Financial StatementsNews
Labcorp price target raised to $355 from $306 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Labcorp (LH) to $355 from $306 and keeps a Hold rating on the shares.
Labcorp price target raised to $420 from $380 at UBS
UBS analyst Kevin Caliendo raised the firm’s price target on Labcorp (LH) to $420 from $380 and keeps a Buy rating on the shares.
Labcorp price target raised to $388 from $338 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Labcorp (LH) to $388 from $338 and keeps an Overweight rating on the shares. A “beat and raise” in Q3 reinforces confidence…
Labcorp price target raised to $396 from $361 at Baird
Baird raised the firm’s price target on Labcorp (LH) to $396 from $361 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results. Published…
Labcorp price target raised to $380 from $330 at Barclays
Barclays raised the firm’s price target on Labcorp (LH) to $380 from $330 and keeps an Equal Weight rating on the shares. The firm updated the company’s model post the…
Labcorp price target raised to $410 from $365 at Leerink
Leerink analyst Michael Cherny raised the firm’s price target on Labcorp (LH) to $410 from $365 and keeps an Outperform rating on the shares.
Labcorp Holdings Earnings Call Transcript: Q3 2026
Q3 revenue rose 6.9%, adjusted EPS increased 14.5%, and margins expanded across both segments. FY26 guidance was raised, while the estimated $125M 2027 PAMA impact is expected to be partly offset by growth, productivity and acquisitions.
Labcorp Holdings Earnings release: Q3 2026
Labcorp Holdings released its Q3 2026 earnings on October 28, 2026, summarizing the period's financial results.
Labcorp Holdings Slides: Q3 2026
Labcorp Holdings has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 28, 2026.
Labcorp raises FY26 adjusted EPS view to $18.30-$18.70 from $18.10-$18.55
Consensus $18.35. Raises FY26 revenue view to $14.78B-$14.89B from $14.71B-$14.83B, consensus $14.75B. Backs FY26 free cash flow view $1.24B-$1.36B. The company said, “Labcorp (LH) is updating 2026 fu...
Labcorp reports Q3 adjusted EPS $4.78, consensus $4.64
Reports Q3 revenue $3.81B, consensus $3.76B. “Labcorp (LH) delivered another strong quarter with 7% revenue growth, continued margin expansion and 14.5% adjusted EPS growth, leading to a raise in our…
Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance
Results from operations for third quarter 2026 versus third quarter 2025: Revenue: $3.81 billion vs. $3.56 billion, up 6.9% Diluted EPS: $3.22 vs.
Waters, Labcorp partner to expand access to cervical cancer screening
Labcorp (LH) and Waters (WAT) announced a partnership to expand access to the FDA-approved BD Onclarity HPV Assay through Labcorp’s nationwide laboratory network beginning in late 2026. Cervical cance...
Waters, Labcorp partner to expand access to cervical screening
Labcorp (LH) and Waters (WAT) announced a partnership to expand access to the FDA-approved BD Onclarity HPV Assay through Labcorp’s nationwide laboratory network beginning in late 2026. Cervical cance...
Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026
Labcorp intends to be the first commercial laboratory to offer FDA-approved HPV testing with the BD Onclarity™ HPV Assay across clinician-collected and self-collected screening options in clinic, pati...
Labcorp, Charles River and FDA to collaborate to evaluate drug abuse potential
Labcorp (LH) announced a collaboration with the FDA and Charles River Laboratories (CRL) to advance the science used to evaluate a medicine’s abuse potential, or the likelihood that it could…
Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential
Research collaboration aims to strengthen the science used to assess whether new medicines could be abused, supporting safer drug development and more informed regulatory decisions BURLINGTON, N.C., O...
Labcorp Declares Quarterly Dividend
BURLINGTON, N.C., Oct. 21, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has d...
TD says Myriad Genetics prenatal divestiture proceeds ahead of expectations
After Myriad Genetics (MYGN) announced a deal to sell its Prenatal Health testing business to Labcorp (LH) for $210M in cash plus closing inventory, TD Cowen analyst Kyle Boucher said…
Myriad Genetics to sell Prenatal Health testing business to Labcorp
Myriad Genetics (MYGN) announced a definitive agreement for Myriad to sell its Prenatal Health testing business, which includes the Prequel, Foresight, SneakPeek, and FirstGene tests, to Labcorp (LH) ...
Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
SALT LAKE CITY and BURLINGTON, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and Labcorp (NYSE: LH), a ...
Three stocks poised to beat estimates this earnings season
Third-quarter earnings season has opened unevenly. JPMorgan, Wells Fargo and Citigroup posted missed results this week, while UnitedHealth topped forecasts for both revenue and profit.
Labcorp to acquire laboratory testing assets of Opko Health subsidiary
Labcorp (LH) and OPKO Health (OPK) have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health. Through this transaction,…
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health
Acquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwide BURLINGTON, N.C. and MIAMI, Fla.
Labcorp and Arianna Huffington's Thrive Global Collaborate to Launch Thrive 5 Health Test
First lab test offered in collaboration with Thrive Global Combines Labcorp's scientific expertise with Thrive Global's behavior change approach to help consumers turn health insights into healthier d...